Qiagen touts expanded uses for SARS-CoV-2, tuberculosis tests

By LabPulse.com staff writers

January 7, 2022 -- Qiagen is touting new additions to the growing number of applications for its QIAcuity digital polymerase chain (PCR) reaction platform. The firm also outlined expansion initiatives for its QuantiFeron technology.

QIAcuity is the company's digital PCR platform that uses nanoplates to process samples in two hours. Qiagen recently entered into two new collaborations that aim to extend the platform's ecosystem.

One collaboration is with Atila BioSystems, which provides noninvasive prenatal testing solutions that require only a blood sample from the mother. The goal is to replace more invasive testing methods such as amniocentesis that can endanger the fetus and mother.

The other collaboration is with German startup Actome, which extends QIAcuity's reach into proteomics. This allows for proteins to be quantified and interactions between different proteins, as well as between proteins and target genes, to be analyzed, the company said.

Qiagen's QuantiFeron franchise, meanwhile, experienced recent new developments in COVID-19 and tuberculosis testing. The company reported "strong customer interest" in its QuantiFERON SARS-CoV-2 assay, which was launched in December 2021. The assay recently received a European CE Mark.

This test measures T-cell responses to SARS-CoV-2 and helps assess immunity in individuals who have received COVID-19 vaccination, the company said.

The U.S. Food and Drug Administration (FDA) also recently expanded the range of target groups that can be tested with Qiagen's blood-based QuantiFeron-TB Gold assay for detecting tuberculosis. These now include individuals with weakened immune systems, pregnant women, and children.

The company's battery-operated QIAreach QuantiFeron-TB test for tuberculosis has also been approved by the Global Fund's Expert Review Panel Diagnostics, meaning the test can be obtained by public health programs and institutions in more than 100 countries that qualify for Global Fund or Unitaid resources. It can also be made available through the Stop TB Partnership's Global Drug Facility.

Fauci, health agencies confirm current PCR tests detect omicron
As the world grapples with yet another coronavirus variant -- this time omicron -- there is some good news. Companies and health agencies are attesting...
Qiagen, DiaSorin partner on TB screening
The U.S. Food and Drug Administration has approved Qiagen's Liaison QuantiFeron-TB Gold Plus assay for use on DiaSorin's automated Liaison XS platform....
Qiagen and BD settle PCR patent lawsuit
Qiagen and Becton Dickinson (BD) have reached a settlement in a patent infringement lawsuit involving polymerase chain reaction (PCR) tests that Qiagen...
Qiagen launches new tuberculosis test
Qiagen has launched a new test to detect tuberculosis (TB) infection, which also received a CE Mark.
Qiagen reaches biological sample milestone
Qiagen's consumables kits have now been used to process more than 3 billion biological samples. Furthermore, the company's next-generation sequencing...

Copyright © 2022 LabPulse.com

Last Updated ls 1/7/2022 1:36:13 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current